These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 6762661)

  • 21. In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin.
    Wise R; Andrews JM; Bedford KA
    Antimicrob Agents Chemother; 1978 Mar; 13(3):389-93. PubMed ID: 122520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In vitro susceptibilities of BRL 25000 (clavulanic acid-amoxicillin) against causative organisms in the field of obstetrics and gynecology].
    Deguchi K; Fukayama S; Nishimura Y; Yokota N; Tanaka S; Yoshihara H; Oda S; Matsumoto Y; Ikegami R; Sato K
    Jpn J Antibiot; 1986 Mar; 39(3):842-52. PubMed ID: 3488425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitivity to augmentin and cephalosporines of some bacterial strains isolated from hospitalized patients.
    Debeleac L; Iancu A; Tudorache D; Iancu G
    Rom J Intern Med; 1995; 33(3-4):227-35. PubMed ID: 8646195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-vitro activity of augmentin against clinically important gram-positive and gram-negative bacteria in comparison with other antibiotics.
    Focht J; Klietmann W; Heilmann HD
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Apr; 256(4):523-30. PubMed ID: 6564828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antimicrobial activities of clavulanic acid/amoxicillin against freshly isolated clinical strains from outpatients].
    Koguchi M; Suzuki Y; Tanaka S; Fukayama S; Ishihara R; Deguchi K; Oda S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1995 Dec; 48(12):1920-34. PubMed ID: 8587166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complementary activity of mezlocillin and the combination of amoxicillin with clavulanic acid on Enterobacteriaceae.
    Roy C; Foz A; Tirado M; Fuster C; Segura C
    Infection; 1982; 10 Suppl 3():S262-6. PubMed ID: 6218121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experimental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) in the pediatric field].
    Iwai N; Taneda Y; Shibata M; Mizoguchi F; Katayama M
    Jpn J Antibiot; 1985 Feb; 38(2):342-58. PubMed ID: 3847522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF; Wildfeuer A
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microcalorimetric, turbidimetric, phase-contrast microscopic, and electron microscopic investigations of the actions of amoxicillin, clavulanic acid and augmentin on amoxicillin-sensitive and amoxicillin-resistant strains of Escherichia coli.
    Semenitz E; Casey PA; Pfaller W; Gstraunthaler G
    Chemotherapy; 1983; 29(3):192-207. PubMed ID: 6347546
    [No Abstract]   [Full Text] [Related]  

  • 30. [Comparison of the in vitro activity of amoxycillin + clavulanic acid and ampicillin + sulbactam combinations against 50 Haemophilus influenzae strains producing beta lactamase].
    Moittie D; Simonet M; Veron M
    Pathol Biol (Paris); 1989 May; 37(5):390-3. PubMed ID: 2789362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prevalence of beta-lactamase producing bacteria in subgingival plaque and their sensitivity to Augmentin.
    Legg JA; Wilson M
    Br J Oral Maxillofac Surg; 1990 Jun; 28(3):180-4. PubMed ID: 1983762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antibacterial activities of monobactams against fresh clinical isolates].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukayama S; Nishimura Y; Oda S; Tanaka S; Kato M; Sato K
    Jpn J Antibiot; 1988 Nov; 41(11):1600-22. PubMed ID: 3210297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial susceptibility testing of Haemophilus influenzae: trial organised as part of United Kingdom national external quality assessment scheme for microbiology.
    Snell JJ; Brown DF; Phua TJ
    J Clin Pathol; 1986 Sep; 39(9):1006-12. PubMed ID: 3489739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Saunders KA; Miller LA; Poupard JA;
    Int J Antimicrob Agents; 2003 May; 21(5):425-33. PubMed ID: 12727075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent beta-lactamase inhibitor. II. Antibacterial properties.
    Angehrn P; Arisawa M
    J Antibiot (Tokyo); 1982 Nov; 35(11):1584-9. PubMed ID: 6298168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sensitivity to clavulanic acid of Escherichia coli isolated at the Henri Mondor hospital in 1986 according to phenotypes of beta-lactam antibiotic resistance].
    Soussy CJ; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1988 May; 36(5):442-5. PubMed ID: 3043340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Susceptibility of clinically-isolated problem pathogenic bacteria to broad spectrum antibiotics].
    Fazli SA; Aksebzeci T
    Mikrobiyol Bul; 1989 Oct; 23(4):356-60. PubMed ID: 2488944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of the amoxicillin-gentamicin combination in the presence of clavulanic acid on 8 strains of amoxicillin-resistant bacteria].
    Deforges L; Soussy CJ; Duval J
    Pathol Biol (Paris); 1984 Jun; 32(5 Pt 2):496-500. PubMed ID: 6379567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [beta-lactamase-producing activity and antimicrobial susceptibility of major pathogenic bacteria isolated from clinical samples. Japan beta-lactamase Research Group].
    Oguri T; Igari J; Hiramatsu K; Watanabe A; Inoue M; Abe M; Yamane N; Aihara M; Hashimoto H;
    Jpn J Antibiot; 2002 Sep; 55 Suppl A():1-28. PubMed ID: 12599526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.